Immunoglobulins Market

Immunoglobulins Market Outlook (2023 to 2033)

Global demand for immunoglobulins is predicted to increase at a CAGR of 6.8% from 2023 to 2033. The global immunoglobulins market is valued at US$ 14 billion in 2023 and is thus expected to reach US$ 27 billion by 2033-end. The use of immunoglobulins in hospitals is increasing because they facilitate the better supervision of patients who are undergoing infusions and are cost-effective.

An immunoglobulin, also known as an antibody, is a biologically generated protein by plasma cells and other lymphocytes that the immune system uses to identify and eliminate microorganisms that cause disease. Commercial immunoglobulin is a blood product that is fractionated and purified for use in therapeutic and research procedures.

The emergence of improved purification procedures that provide a higher yield of plasma and the increase in immunodeficiency disease prevalence are the key drivers of the worldwide market for immunoglobulins. Additionally, immunoglobulins help spatial genomic analysis provide a biomarker for cancer diagnostics, whose rising demand is anticipated to fuel the expansion of the immunoglobulins market. Another factor driving market growth is the usage of the products in the treatment of neurological illnesses.

It is anticipated that the market would rise due to advancements in the field of research and development for the development of new products for the control of diseases. The market for immunoglobulins is predicted to expand quickly as a result of rising immunoglobulin use and expanding research and development efforts.

Spatial information is being used as a diagnostic biomarker for a variety of diseases as a result of the identification of the spatial patterns of the genome for treating different medical problems. The need for more accurate biomarkers that can distinguish between benign and malignant tumors is growing, which is raising the demand for spatial genomic analysis as a cancer diagnostic tool. As a result, the growing need for reliable cancer diagnostic tools is contributing to market expansion.

Glycoproteins known as immunoglobulins are formed in the blood plasma. In turn, this response to body-present antigens. These immunoglobulins are given to patients with weakened immune systems. An illness such as immunodeficiency may be inherited by the body or result from exposure to infections through bodily fluids, chemotherapy, and cancer medications.

Fast food consumption is increasing among people as a result of increased urbanization and busy schedules. One of the main factors driving the growth of the market is this, along with sedentary lifestyles and a rise in patients with illnesses such as multiple myeloma, and autoimmune disorders.

Rising interest in customized treatment and increased awareness of the need for early diagnosis are further factors driving market expansion. Additionally, the body is assisted in fighting many infectious diseases by immunoglobulins through many administration methods. In addition, several pharmaceutical companies are releasing modern immunoglobulins for the treatment of neurological illnesses that are more effective and advanced.

Report Attributes	Details
Immunoglobulins Market Size (2023)	US$ 14 Billion
Projected Market Value (2033)	US$ 27 Billion
Global Market Growth Rate (2023 to 2033)	6.8% CAGR
Market Share of Intravenous Immunoglobulin Administration	60%
Key Companies Profiled	Grifols, S.A.; Octapharma; Kedrion Biopharma Inc.; Biotest AG; Sanquin; Abeona Therapeutics; Baxter International Inc.; CSL Behring; Evolve Biologics Inc.

Which are the Growth Determinants of the Market for Immunoglobulins?

“Increasing Prevalence of Immunological Disorders and Expanding Geriatric Population”

An increase in immunological disorders has led people to seek out advanced medical care, increasing the market share for immunoglobulins. The use of intravenous and subcutaneous immunoglobulins has significantly increased for off-label indications.

Global healthcare systems are extremely concerned about the growing senior population as well as the rising frequency of immunodeficiency and neurological illnesses. Thus, there is a rise in demand for novel intravenous immunoglobulin therapies due to increased awareness and the need to ensure effective treatment, which is anticipated to drive market revenue growth.

The market for immunoglobulins will experience significant expansion due to an increase in hemophiliac patients. The market for immunoglobulins may experience exponential expansion if immunoglobulin therapy becomes the preferred treatment for immunodeficiency and other rare neurological illnesses. Rapid regulatory approvals are also enhancing market growth potential.

Increasing prevalence of primary immunodeficiency disease (PID) around the world is another important factor influencing market expansion. In addition, the aging population, which is more susceptible to disease because their bodies have weak immune systems, is driving up the demand for immunoglobulin.

“Rapid Adoption of Innovative Immunoglobulin Therapies”

The adoption of innovative immunoglobulin therapies is increasing among medical professionals. It is regarded as the first line of treatment in patients with chronic inflammatory demyelinating polyneuropathy due to its efficacy.

There has been a rise in the demand for immunoglobulins as a therapy option due to higher awareness and an increase in diagnoses as a result of improved diagnostic techniques. Immunomodulation and anti-inflammatory characteristics of immunoglobulins are some other aspects that are assisting in the rise of the market for these substances.

The use of immunoglobulins is expanding, which is gaining traction among pharmaceutical and biopharmaceutical companies for immunoglobulin research and development. It is projected that an increase in intravenous product approvals and clinical trials for novel clinical uses would offer the industry substantial growth possibilities.

Market expansion is driven by high-tech healthcare facilities, rising public and private investments, growing usage of subcutaneous immunoglobulins, and surging popularity of enhanced immunotherapies. Increased financing for R&D projects and enhancing healthcare infrastructure are boosting market value.

What is Hampering the Demand for Immunoglobulins?

to be negatively impacted by the high cost of therapies. The market for immunoglobulins will face challenges from a lack of qualified personnel and the increased risk of adverse reactions associated with immunoglobulin use.

Which Region Provides Lucrative Opportunities for Market Players?

“Significant Reimbursement Coverage Boosting Market Value in North America”

North America accounts for 50% share of the global immunoglobulins market owing to the high prevalence of neurological, immunological, and other disorders, a rise in the local supply of intravenous immunoglobulin products, and significant reimbursement coverage along with the presence of major market players. New developments in antibody therapy, increased consumer awareness of personal health, and medical innovations are driving market growth in the region.

Country-wise Insights

Why is the Adoption of Immunoglobulins Surging in the United States?

“Development of Plasma Biocentres in the Country”

Increasing consumer awareness of the medicines used to treat immunodeficiency illnesses and growing preference among physicians for immunodeficiency therapies are the main factors propelling market growth in the United States. The development of plasma biocentres, plasma collection sites, and specialized infusion facilities is anticipated to accelerate market expansion in the United States.

How is Germany Aiding Market Growth in Europe?

“Increasing Government Investments in Advanced Medical Therapies”

The market in Germany is anticipated to experience consistent revenue growth due to the growing adoption of immunoglobulin therapy among the median-age population. Increasing government investments in advanced medical therapies will fuel market expansion over the projection period.

Will Japan be an Investment-worthy Market for Immunoglobulin Producers?

“Growing Adoption of Blood & Plasma Collection Techniques”

Rapid development of healthcare infrastructure, growing adoption of blood and plasma collection techniques, and increasing geriatric population are the key drivers augmenting market growth in Japan. Rising R&D expenditures, the presence of plasma fractionation facilities, growing awareness of blood donation and its potential use in creating life-saving products, and rising disposable income are supporting market growth.

Category-wise Insights

Which Route of Administration is Forecast to Gain the Prominent Market Share?

“Intravenous Immunoglobulin Administration Preferred Due to High Effectiveness & Bioavailability”

By route of administration, the market is segmented into intravenous, subcutaneous, and intramuscular. Intravenous immunoglobulin administration accounts for 60% share of the global market owing to the rise in strategic initiatives involving intravenous immunoglobulin and the rapid absorption rate provided by intravenous delivery.

Approval of intravenous immunoglobulin (IVIG) products for chronic and rare diseases is projected to uplift the market. An injection or infusion form of drug administration into the vein by a needle or tube is referred to as an intravenous route of administration. A substance produced of antibodies that can be administered intravenously is called intravenous immunoglobulin.

The most popular type of immunoglobulin used to treat immunodeficiency and autoimmune illnesses is intravenous immunoglobulin (IVIG). Since immunoglobulins have been suggested for therapeutic use, they have been delivered intravenously, which offers high effectiveness and bioavailability.

Which Application Will Emerge as Key Market Contributor?

“Immunoglobulins Widely Used in Neurology Owing to Growing Prevalence of Rare Neurological Disorders”

Based on application, the market is divided into neurology, immunology, hematology, and others. High usage of immunoglobulins in neurology is attributed to the increasing prevalence of neurological conditions, including multifocal motor neuropathy and chronic inflammatory demyelinating polyneuropathy (CIDP). Intravenous, subcutaneous and intramuscular immunoglobulins are effective for the treatment of rare neurological disorders.

Competitive Landscape

Leading companies are concentrating on molecular immunoglobulin indications and quality control of pipeline products following safety regulations to lower the environmental impact. To expand their presence in developing regions, key market players are focusing on supply chain management and enhancing product standards.

Top immunoglobulin producers are offering technologically advanced methods and platforms for a better understanding of disease biology and the introduction of innovative therapies. Top vendors in the industry need to obtain plasma for fractionation. Wide-spread installations of plasma collecting facilities can be made throughout the countries, enabling the collection of greater volumes of plasma.

For instance,

• Grifols S.A. manufactures Gamunex C and Flebogamma Intravenous immunoglobulin products. Gamunex C is a sterilized solution made from human plasma that contains antibodies to treat primary immunodeficiency.
• CSL Behring is engaged in producing subcutaneous immunoglobulin products such as Privigen, Evogam, and Beriglobin P. Berigloin P is presented in the form of an injection containing excipients of glycine, sodium chloride, hydrochloric acid, or sodium hydroxide and water.
• In 2019, the United States Food and Drug Administration granted Kedrion Biopharma permission to perform a clinical trial to evaluate the effectiveness and safety of a 10% intravenous immunoglobulin in the treatment of individuals with primary immunodeficiency illnesses.
• In 2022, the indication for Octapharma's cutaquig was enhanced by the European Union. It is a human immunoglobulin intended for subcutaneous use. Patients with any kind of secondary immunodeficiency who require immunoglobulin replacement therapy are covered by the expanded indication.

Key Segments of Immunoglobulins Industry Research

• By Administration :

  • Intravenous
  • Subcutaneous
  • Intramuscular

• By Application :

  • Neurology
  • Immunology
  • Hematology
  • Others

• By End User :

  • Hospitals
  • Clinics
  • Homecare

• By Region :

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa